158 related articles for article (PubMed ID: 10482355)
1. Antisense strategies: functions and applications in immunology.
Varga LV; Tóth S; Novák I; Falus A
Immunol Lett; 1999 Aug; 69(2):217-24. PubMed ID: 10482355
[TBL] [Abstract][Full Text] [Related]
2. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Brysch W; Schlingensiepen KH
Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide therapeutics: clothing the emperor.
Gewirtz AM
Curr Opin Mol Ther; 1999 Jun; 1(3):297-306. PubMed ID: 11713794
[TBL] [Abstract][Full Text] [Related]
4. [The application of antisense technology in ophthalmology].
Guo Y; Ge J
Yan Ke Xue Bao; 1998 Jun; 14(2):108-15. PubMed ID: 12580046
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
7. Antisense-mediated redirection of mRNA splicing.
Vacek M; Sazani P; Kole R
Cell Mol Life Sci; 2003 May; 60(5):825-33. PubMed ID: 12827272
[TBL] [Abstract][Full Text] [Related]
8. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.
Zon G
Mol Neurobiol; 1995; 10(2-3):219-29. PubMed ID: 7576309
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
Stein CA; Cheng YC
Science; 1993 Aug; 261(5124):1004-12. PubMed ID: 8351515
[TBL] [Abstract][Full Text] [Related]
10. Specific inhibition of oncogene expression in vitro and in vivo by antisense oligonucleotides.
Neckers L; Rosolen A; Fahmy B; Whitesell L
Ann N Y Acad Sci; 1992 Oct; 660():37-44. PubMed ID: 1340154
[No Abstract] [Full Text] [Related]
11. Antisense-protein kinase A: a single-gene-based therapeutic approach.
Cho-Chung YS; Nesterova M; Kondrashin A; Noguchi K; Srivastava R; Pepe S
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):217-23. PubMed ID: 9212914
[No Abstract] [Full Text] [Related]
12. Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression.
Hung WC; Huang JS; Chuang LY
Biochem Biophys Res Commun; 1996 Mar; 220(3):719-23. PubMed ID: 8607831
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic implications of antisense oligonucleotides.
Lattuada D; Mazzei M; Meazza R; Nicolin A
Int J Clin Lab Res; 1992; 21(4):296-9. PubMed ID: 1591383
[TBL] [Abstract][Full Text] [Related]
14. Application of antisense technology to therapeutics.
Heidenreich O; Kang SH; Xu X; Nerenberg M
Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
[TBL] [Abstract][Full Text] [Related]
15. Antisense nucleic acids targeted to the thymidylate synthase (TS) mRNA translation start site stimulate TS gene transcription.
DeMoor JM; Vincent MD; Collins OM; Koropatnick J
Exp Cell Res; 1998 Aug; 243(1):11-21. PubMed ID: 9716444
[TBL] [Abstract][Full Text] [Related]
16. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
19. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
20. Autoinduction of platelet derived growth factor (PDGF) A-chain mRNA expression in a human malignant melanoma cell line and growth inhibitory effects of PDGF-A-chain mRNA-specific antisense molecules.
Behl C; Bogdahn U; Winkler J; Apfel R; Brysch W; Schlingensiepen KH
Biochem Biophys Res Commun; 1993 Jun; 193(2):744-51. PubMed ID: 8512572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
